BML Capital Management LLC Acquires 50,000 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

BML Capital Management LLC raised its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 50.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Vistagen Therapeutics accounts for approximately 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 22nd biggest holding. BML Capital Management LLC’s holdings in Vistagen Therapeutics were worth $771,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Schonfeld Strategic Advisors LLC acquired a new position in shares of Vistagen Therapeutics during the third quarter worth $726,000. Blair William & Co. IL acquired a new position in shares of Vistagen Therapeutics during the third quarter worth $446,000. Finally, Raymond James & Associates acquired a new position in shares of Vistagen Therapeutics during the third quarter worth $52,000. 78.39% of the stock is owned by institutional investors and hedge funds.

Vistagen Therapeutics Stock Up 1.0 %

Shares of VTGN stock opened at $4.83 on Wednesday. The business’s fifty day simple moving average is $4.78 and its 200-day simple moving average is $4.43. Vistagen Therapeutics, Inc. has a 12-month low of $1.62 and a 12-month high of $24.71.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Tuesday, February 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.09. The business had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.73 million. Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. As a group, research analysts forecast that Vistagen Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.